Subgroup Classification and Therapeutic Guidance for Myasthenia Gravis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Myasthenia gravis (MG) is a chronic autoimmune disease of neuromuscular blockade, characterized by muscle weakness and fatigue, and is associated with the production of autoantibodies against the skeletal muscle acetylcholine receptor, muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), and other muscle endplate proteins. In addition, MG may be classified according the location of the affected muscles (ocular vs. generalized), patient age at symptom onset, and thymic pathology. Subgroup classification based on serum antibodies and clinical features include early-onset, late-onset, thymoma-associated, MuSK and LRP4 antibody-negative, and ocular forms of MG, and can help with therapeutic decisions and prognosis. Pyridostigmine is the chosen symptomatic treatment. For patients who do not adequately respond to symptomatic therapy, corticosteroids, other immunomodulating agents, and thymectomy are the first-line immunosuppressive treatments. The treatment of MG is highly individualized and depends on the age of the patient, the type and severity of the disease, and the pace of progression.
Abstract
Myasthenia gravis (MG) is a chronic autoimmune disease of neuromuscular blockade, characterized by muscle weakness and fatigue, and is associated with the production of autoantibodies against the skeletal muscle acetylcholine receptor, muscle-specific kinase (MuSK), low-density lipoprotein receptor-related protein 4 (LRP4), and other muscle endplate proteins. In addition, MG may be classified according the location of the affected muscles (ocular vs. generalized), patient age at symptom onset, and thymic pathology. Subgroup classification based on serum antibodies and clinical features include early-onset, late-onset, thymoma-associated, MuSK and LRP4 antibody-negative, and ocular forms of MG, and can help with therapeutic decisions and prognosis. Pyridostigmine is the chosen symptomatic treatment. For patients who do not adequately respond to symptomatic therapy, corticosteroids, other immunomodulating agents, and thymectomy are the first-line immunosuppressive treatments. The treatment of MG is highly individualized and depends on the age of the patient, the type and severity of the disease, and the pace of progression.
참고문헌 (38)
- Drachman DB, "Myasthenia gravis", N Engl J Med, 330, pp.1797~1810 (1994)
- Vincent A, "Unravelling the pathogenesis of myasthenia gravis", Nat Rev Immunol, 2, pp.797~804 (2002)
- Luchanok U, "Ocular myasthenia : diagnostic and treatment recommendations and the evidence base", Curr Opin Neurol, 21, pp.8~15 (2008)
- Andrews PI, "Autoimmune myasthenia gravis in childhood", Semin Neurol, 24, pp.101~110 (2004)
- Evoli A, "Acquired myasthenia gravis in childhood", Curr Opin Neurol, 23, pp.536~540 (2010)
- Chiu HC, "Myasthenia gravis : population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians", Neurology, 37, pp.1854~1857 (1987)
- Chiang LM, "Juvenile myasthenia gravis", Muscle Nerve, 39, pp.423~431 (2009)
- Andrews PI, "Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis", Neurology, 44, pp.1208~1214 (1994)
- Gilhus NE, "Myasthenia gravis : subgroup classification and therapeutic strategies", Lancet Neurol, 14, pp.1023~1036 (2015)
- Lee KY, "Acetylcholine receptor antibody and clinical features in childhood onset myasthenia gravis", J Korean Child Neurol Soc, 13, pp.210~219 (2005)
- Vincent A, "Antibody heterogeneity and specificity in myasthenia gravis", Ann N Y Acad Sci, 505, pp.106~120 (1987)
- McConville J, "Detection and characterization of MuSK antibodies in seronegative myasthenia gravis", Ann Neurol, 55, pp.580~584 (2004)
- Ghazanfari N, "Muscle specific kinase : organiser of synaptic membrane domains", Int J Biochem Cell Biol, 43, pp.295~298 (2011)
- Evoli A, "Myasthenia gravis with antibodies to MuSK: another step toward solving mystery?", Neurology, 77, pp.1783~1784 (2011)
- Deymeer F, "Clinical comparison of anti-MuSK-vs anti-AChR-positive and seronegative myasthenia gravis", Neurology, 68, pp.609~611 (2007)
- Pevzner A, "Anti-LRP4 autoantibodies in AChR-and MuSKantibody-negative myasthenia gravis", J Neurol, 259, pp.427~435 (2012)
- Zhang B, "Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis", Arch Neurol, 69, pp.445~451 (2012)
- Gasperi C, "Anti-agrin autoantibodies in myasthenia gravis", Neurology, 82, pp.1976~1983 (2014)
- Madhavan R, "The function of cortactin in the clustering of acetylcholine receptors at the vertebrate neuromuscular junction", PLoS One, 4, pp.e8478~ (2009)
- Skeie GO, "Guidelines for treatment of autoimmune neuromuscular transmission disorders", Eur J Neurol, 17, pp.893~902 (2010)
- Breiner A, "Epidemiology of myasthenia gravis in Ontario, Canada", Neuromuscul Disord, 26, pp.41~46 (2016)
- Mantegazza R, "A multicentre follow-up study of 1152patients with myasthenia gravis in Italy", J Neurol, 237, pp.339~344 (1990)
- Keesey JC, "Clinical evaluation and management of myasthenia gravis", Muscle Nerve, 29, pp.484~505 (2004)
- Grob D, "Lifetime course of myasthenia gravis", Muscle Nerve, 37, pp.141~149 (2008)
- Lindner A, "Outcome in juvenile-onset myasthenia gravis : a retrospective study with long-term followup of 79 patients", J Neurol, 244, pp.515~520 (1997)
- Evoli A, "Juvenile myasthenia gravis with prepubertal onset", Neuromuscul Disord, 8, pp.561~567 (1998)
- Sommer N, "Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects", Doc Ophthalmol, 84, pp.309~333 (1993)
- Finnis MF, "Juvenile myasthenia gravis : a paediatric perspective", Autoimmune Dis, 2011, pp.404101~ (2011)
- Mahadeva B, "Autoimmune disorders of neuromuscular transmission", Semin Neurol, 28, pp.212~227 (2008)
- AAEM Quality Assurance Committee, "Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome", Muscle Nerve, 24, pp.1239~1247 (2001)
- Della Marina A, "Juvenile myasthenia gravis : recommendations for diagnostic approaches and treatment", Neuropediatrics, 45, pp.75~83 (2014)
- Sanders DB, "International consensus guidance for management of myasthenia gravis : executive summary", Neurology, 87, pp.419~425 (2016)
- Lim BC, "Childhood myasthenia gravis : clinical features and response to steroid treatment", J Korean Child Neurol Soc, 11, pp.120~127 (2003)
- Díaz-Manera J, "Treatment strategies for myasthenia gravis : an update", Expert Opin Pharmacother, 13, pp.1873~1883 (2012)
- Illa I, "IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status", J Neurol, 252(Suppl 1), pp.I14~I18 (2005)
- Saperstein DS, "Management of myasthenia gravis", Semin Neurol, 24, pp.41~48 (2004)
- Tracy MM, "Graded response to thymectomy in children with myasthenia gravis", J Child Neurol, 24, pp.454~459 (2009)
- Hennessey IA, "Thymectomy for inducing remission in juvenile myasthenia gravis", Pediatr Surg Int, 27, pp.591~594 (2011)